Using mobile phones to fight Alzheimer’s disease
Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.
Future treatments for age-related dementia could involve mobile phone frequency electromagnetic fields, researchers at Nazarbayev University and the National Laboratory Astana investigate.
The scientists are studying how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy, selecting a frequency of 918 MHz because it’s commonly used in mobile phones.
Alzheimer’s disease, the most common form of age-related dementia, is usually characterised by loss of memory and dramatic changes in character and behaviour, eventually leading to an inability to carry out normal daily life activities. The cause of the disease is the accumulation of the toxic beta-amyloid peptide in brain tissues, which leads to oxidative stress, neuroinflammation, mitochondrial dysfunction, and ultimately – the death of nerve cells.
The study provides insight into what happens when an electromagnetic field of 918 MHz frequency suppresses oxidative stress triggered by beta-amyloid.
Researcher Andrey Tsoy says: “Building on the work of scientists from the USA, who conducted experiments with the same parameters in a 6-month period, we used human and rat cultures – model cells – and shorter exposure periods of 60 minutes. The results of our studies, obtained by irradiation of cells with an electromagnetic field frequency of 918 MHz in a period of up to 24 hours, confirmed the ability of the electromagnetic field to suppress oxidative stress, which indicates the possible therapeutic effect.
“Thus, irradiation with an electromagnetic field frequency of 918 MHz can probably be used in the treatment of Alzheimer’s disease patients.”
Nazarbayev University’s scientists plan to continue research in this direction and confirm whether these methods can be implemented in the fight against the devastating disease.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance